Antimicrobial Agents and Chemotherapy

View all AAC RSS

Reply to Külls et al., “Residual confounding and outcome definition in observational comparisons of PDR-Acinetobacter baumannii therapies”
by Konstantinos PontikisIlias KaraiskosHelen GiamarellouGeorge L. Daikos1Intensive Care Unit 1st Department of Pulmonology, Chest Diseases Hospital "I Sotiria," National and Kapodistrian University of Athens68993https://ror.org/04gnjpq42, Athens, Greece21st Department of Internal Medicine–Infectious Diseases, Hygeia General Hospital, Athens, Greece32nd Department of Internal Medicine, Mitera General Hospital, Athens, GreeceCesar A. Arias on March 16, 2026 at 7:00 am
Reply to Lai and Huang, “Which beta-lactam infusion strategy is superior in ICU pneumonia? A Bayesian network meta-analysis of continuous, extended, and intermittent approaches”
by Yixuan LiJason A. RobertsMohd H. Abdul-AzizFekade B. Sime1University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland1974https://ror.org/00rqy9422, Brisbane, Australia2Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia3Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women’s Hospitalhttps://ror.org/05p52kj31, Brisbane, Australia4Division of Anesthesia Critical Care and Emergency and Pain Medicine, UR UM 103, University of Montpellier, Nimes University Hospitalhttps://ror.org/051escj72, Nimes, France5School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, Brisbane, Queensland, AustraliaJames E. Leggett on March 16, 2026 at 7:00 am
Which beta-lactam infusion strategy is superior in ICU pneumonia? A Bayesian network meta-analysis of continuous, extended, and intermittent approaches
by Pei-Chun LaiYen-Ta Huang1Education Centre, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University34912https://ror.org/01b8kcc49, Tainan City, Taiwan2Department of Paediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University34912https://ror.org/01b8kcc49, Tainan City, Taiwan3Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University34912https://ror.org/01b8kcc49, Tainan City, TaiwanJames E. Leggett on March 16, 2026 at 7:00 am
Residual confounding and outcome definition in observational comparisons of PDR-Acinetobacter baumannii therapies
by Carsten KüllsNiloufar DadashpourMajid Golestanieraghi1Department of Anaesthesiology and Critical Care, Helios Klinikum Schleswig440814, Schleswig, GermanyCesar A. Arias on March 16, 2026 at 7:00 am
The collective creativity of Drs. Baro, Pooput, and Callaghan
by Paul D. Roepe1Department of Chemistry, Georgetown University8368https://ror.org/05vzafd60, Washington, DC, USA2Department of Biochemistry & Cellular & Molecular Biology, Georgetown University8368https://ror.org/05vzafd60, Washington, DC, USAAudrey Odom John on March 16, 2026 at 7:00 am
Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges
by Bryan P. WhiteEmily A. Siegrist1Department of Pharmacy, University of Oklahoma Medical Center6186https://ror.org/02aqsxs83, Oklahoma City, Oklahoma, USASarah Doernberg on March 16, 2026 at 7:00 am
Deciphering the multidrug resistance paradigm in Candida auris
by Darian J. SantanaNicholas C. CauldronP. David RogersChristina A. Cuomo1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital5417https://ror.org/02r3e0967, Memphis, Tennessee, USA2Department of Molecular Microbiology and Immunology, Brown University6752https://ror.org/05gq02987, Providence, Rhode Island, USADamian J. Krysan on March 16, 2026 at 7:00 am
Reply to Roepe, “The collective creativity of Drs. Baro, Pooput, and Callaghan”
by Iqbal Taliy JunaidAshutosh PandaArunaditya DeshmukhRahila SardarMonika NarwalPrakhar AgrawalNeha PrakashAsif AkhtarAmit Kumar DeySuneet Shekhar SinghSaptarshi MridhaJigneshkumar MochiSadaf ParveenMohit KumarRashi NagarNaseem GaurDinesh GuptaAsif MohmmedInderjeet KaurKrishanpal KarmodiyaPawan Malhotra1Malaria Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB)28845, New Delhi, India2Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology28845https://ror.org/001575385, New Delhi, India3Parasite Cell Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB)28845, New Delhi, India4Department of Biology, Indian Institute of Science Education and Research193158https://ror.org/028qa3n13, Pune, Maharashtra, India5Yeast Biofuel Group, International Centre for Genetic Engineering and Biotechnology28845https://ror.org/001575385, New Delhi, India6Department of Biotechnology, Central University of Haryana242287https://ror.org/03mtwkv54, Mahendergarh, Haryana, IndiaAudrey Odom John on March 16, 2026 at 7:00 am
Reply to White and Siegrist, “Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges”
by Cesar A. AriasTruc T. TranPaul KinsellaBenjamin P. HowdenWilliam R. Miller1Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital23534, Houston, Texas, USA2Center for Infectious Diseases, Houston Methodist Research Institute167626, Houston, Texas, USA3Department of Medicine, Weill Cornell Medical College12295, New York, New York, USA4Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity534133, Melbourne, Australia5Microbiology Department, Royal Melbourne Hospital90134https://ror.org/005bvs909, Melbourne, Australia6Department of Infectious Diseases and Immunology, Austin Health3805https://ror.org/05dbj6g52, Heidelberg, AustraliaSarah Doernberg on March 16, 2026 at 7:00 am
PaREx: an open-source pipeline for the automated analysis of Pseudomonas aeruginosa resistomes from whole-genome sequences
by Carla López-CausapéMatias BonetBiel TaltavullPaola Medina-RetigaMiquel A. Sastre-FemeníaSara Cortés-LaraMaría A. Gomis-FontFernando Gomez-RomanoAntonio Oliver1Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears375118https://ror.org/05jmd4043, Palma de Mallorca, Spain2CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III38176https://ror.org/00ca2c886, Madrid, Spain3OceanDrivers, Palma de Mallorca, SpainLaurent Poirel on March 16, 2026 at 7:00 am
Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield
by Yanka E. A. R. SalazarAntonio M. RezendeMaria C. S. B. PuçaJaime LouzadaMaria E. P. MascarenhasSonja LagströmDanielle FletcherJoseli Oliveira-FerreiraJosé P. GilTais N. de Sousa1Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz154611, Belo Horizonte, Minas Gerais, Brazil2Karolinska Institutet27106https://ror.org/056d84691, Solna, Sweden3Universidade Federal de Roraima89110https://ror.org/03ehp1h78, Boa Vista, Roraima, Brazil4Agilent Technologies Sweden AB105662, Sundbyberg, Sweden5Instituto Oswaldo Cruz, Fundação Oswaldo Cruz154611, Rio de Janeiro, Brazil6Institute of Hygiene and Tropical Medicine, Nova University of Lisbon50106, Lisbon, PortugalAudrey Odom John on March 12, 2026 at 7:00 am
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae
by Linxin YaoTingli TianDanyang ZouXinying LuNanyan JiangXin FengTong ZhengZhuojun TangYi LinZhen NingJianping JiangMeiping YePingyu Zhou1STD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine481875https://ror.org/03rc6as71, Shanghai, China2Department of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine56694https://ror.org/0220qvk04, Shanghai, China3Division of Tuberculosis and HIV/AIDS Prevention, Shanghai Municipal Center for Disease Control and Prevention117753https://ror.org/04w00xm72, Shanghai, China4Institute of Antibiotics, Huashan Hospital, Fudan University12478https://ror.org/013q1eq08, Shanghai, ChinaAnne-Catrin Uhlemann on March 11, 2026 at 7:00 am
Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis
by Mahmoud Tareq AbdelwahabElin M. SvenssonAndreas H. DiaconAlmarie ConradieMorounfolu OlugbosiRodney DawsonGary MaartensPaolo Denti1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town71984https://ror.org/03p74gp79, Cape Town, South Africa2Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center6034https://ror.org/05wg1m734, Nijmegen, the Netherlands3Department of Pharmacy, Uppsala University8097https://ror.org/048a87296, Uppsala, Sweden4Task728678, Bellville, South Africa5Global Alliance for TB Drug Development486654https://ror.org/03ms7cf36, New York, New York, USA6Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute108145https://ror.org/016978714, Cape Town, South AfricaCesar A. Arias on March 9, 2026 at 7:00 am
In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection
by Daniel C. BaileySalvador Castañeda-BarbaKatie E. BarryPuthayalai TreeratMatthew A. CrawfordMolly A. HughesAmy J. Mathers1Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine214842, Charlottesville, Virginia, USA2Clinical Microbiology Laboratory, University of Virginia Health System12350https://ror.org/00wn7d965, Charlottesville, Virginia, USA3Department of Pathology, University of Virginia School of Medicine189557https://ror.org/0153tk833, Charlottesville, Virginia, USAAlita A. Miller on March 5, 2026 at 8:00 am
Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy
by Raphaël SaportaElisabet I. NielsenAnnick MenetreyDavid R. CameronValérie Nicolas-MétralLena E. Friberg1Department of Pharmacy, Uppsala University8097https://ror.org/048a87296, Uppsala, Sweden2Translational Medicine Department, Debiopharm International SA463161, Lausanne, SwitzerlandSarah Doernberg on March 4, 2026 at 8:00 am
Directed evolution of the pathogenic mold Aspergillus fumigatus reveals novel genes contributing to triazole resistance
by Mariana HandelmanArgha SarkarAvital VarshavskyYona ShadkchanXuefei ChenGerard D. WrightEndrews DelbajeBradley LaflammeSara FallahEvelyne CôtéNicole RobbinsThaila Fernanda dos ReisGustavo H. GoldmanLeah E. CowenNir Osherov1Department of Clinical Microbiology and Immunology, Gray School of Medicine, Tel Aviv University26745https://ror.org/04mhzgx49, Tel Aviv, Israel2David Braley Centre for Antibiotics Discovery, M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University3710https://ror.org/02fa3aq29, Hamilton, Ontario, Canada3Departamento de Biologia, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo124589, Ribeirão Preto, São Paulo, Brazil4Department of Molecular Genetics, University of Toronto204248https://ror.org/03dbr7087, , Toronto, Ontario, Canada5Departamento de Bioquímica, Instituto de Química, Universidade Estadual de São Paulohttps://ror.org/02k5swt12, Araraquara, Brazil6Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo67782, Ribeirão Preto, São Paulo, Brazil7National Institute of Science and Technology in Human Pathogenic Fungi, São Paulo, BrazilDamian J. Krysan on March 4, 2026 at 8:00 am
Evaluation of the clinical efficacy, safety, and permeability in pulmonary epithelial lining fluid of contezolid, a novel oxazolidinone drug, in adult patients with pneumonia
by Hailan WuZixuan ChengFengming DingJianlan HuaHailin WangXiannan MengYanmei CaoYuancheng ChenYan ChenBeining GuoTao ChenJing ZhangJing Zhang1Institute of Antibiotics, Huashan Hospital, Fudan University198171https://ror.org/013q1eq08, Shanghai, People's Republic of China2Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People’s Republic of China, Shanghai, People's Republic of China3National Clinical Research Center for Geriatric Diseases, Huashan Hospital, Fudan University159397https://ror.org/013q1eq08, Shanghai, People's Republic of China4Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and lnnovative Drug R&D, Shanghai, People's Republic of China5Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University12478https://ror.org/013q1eq08, Shanghai, People's Republic of China6Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine12482https://ror.org/04a46mh28, Shanghai, People's Republic of China7Shanghai MicuRx Pharmaceutical Co. Ltd, Shanghai, People's Republic of China8Clinical Pharmacology Research Center, Huashan Hospital, Fudan University12478https://ror.org/013q1eq08, Shanghai, People's Republic of China9Shanghai Institute of Infectious Disease and Biosecurity, Fudan University12478https://ror.org/013q1eq08, Shanghai, People's Republic of ChinaJames E. Leggett on March 4, 2026 at 8:00 am
Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model
by Koji TakemotoMami KamadaKeizo MatsushitaHidehito MatsuiJun HidakaHideaki Hanaki1Corporate Regulatory Compliance & Quality Assurance Division, Sumitomo Pharma Co., Ltd.38293, Osaka, Japan2Research and Development Division, Sumitomo Pharma Co., Ltd.38293, Osaka, Japan3Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, JapanJames E. Leggett on March 3, 2026 at 8:00 am
Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects
by Tengrui YinBiao QuQian ZhangSheng XuYijue WuHao JiangYuanyuan HuangWei Hu1Jiangsu Hengrui Medicine Co. Ltd.425579, Lianyungang, People's Republic of China2Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University687310, Hefei, People's Republic of ChinaJames E. Leggett on March 3, 2026 at 8:00 am
Pseudomonas aeruginosa tRNA nucleotidyltransferase Cca controls resistance and tolerance to aminoglycoside antibiotics by regulating the MexXY multidrug efflux pump
by Chenyu ShenLepeng WangYu ZhangLinyan ZhangZhihui ChengWeihui WuUn-Hwan HaShouguang JinYongxin Jin1State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University12538https://ror.org/01y1kjr75, Tianjin, China2Department of Biotechnology and Bioinformatics, Korea University34973https://ror.org/047dqcg40, Sejong, Republic of KoreaLaurent Poirel on March 3, 2026 at 8:00 am